A free white paper from Cerus

While the blood supply can frequently be taken for granted during routine times, there are actions that can be taken now to support patient access to therapeutic plasma and other blood products during future infectious outbreaks or other disasters that place the blood supply under undue stress.

Beyond COVID-19: Plan Now to Future-Proof Your Therapeutic Plasma.
Our new white paper examines these topics in detail:

  • A history of epidemics over the last 20 years
  • The cost and safety advantages of pathogen inactivated plasma compared to the quarantine storage of plasma
  • The value of the INTERCEPT System for convalescent plasma in the treatment of COVID-19
  • Why it's important to prepare now for the pandemics of the future
Preparing for Future Outbreaks

As the coronavirus and other recent epidemics have shown, continuity of the blood supply can be significantly affected in the case of disease outbreaks. Potential blood product shortages, and the resulting impact on patients and healthcare systems, can be minimised by implementing new processes now, such as pathogen inactivation, that will safeguard stocks of therapeutic plasma and other blood products in the case of future outbreaks.

 

 

visuallandingspaginacerus

 

* “Future-Proof Your Therapeutic Plasma” means “Provide a level of pathogen inactivation in the future, identical to the current performance of PI systems”. There has been no pathogen inactivation process that has been shown to eliminate all pathogens.

 

Download white paper

Subscribe to our newsletter